CQIB, Quebec Life Sciences Incubator & Accelerator’s Post

Life Science funding Advent Calendar! Day 2: Not All Investors Are the Same! Are you targeting the right investors? Research is key. Some focus on seed funding, others on growth stages. Venture capitalists, angel investors, or strategic partners—all have different priorities. For example, Novo Holdings focuses on late-stage biotech, while IndieBio funds early-stage innovation. Align your approach with the right investors to save time and energy. Pro Tip: Use LinkedIn’s advanced search to find investors specializing in your field. Tailor your messaging to their expertise and portfolio interests. Who’s your ideal investor? Share below, and let’s refine your target list together! Photo from life science summit at BioStock - Connecting Innovation and Capital #NeuroNata

🚀 Facing challenges navigating the biotech funding landscape? 🧬 In this new episode of #BIOfromtheBAYOU, Ben Kromnick, Head of Healthcare and Life Sciences at Mercury, shares key insights on financing and scaling biotech companies. Learn how biotech startups can secure funding at various growth stages, innovate effectively, and build lasting relationships with investors and partners. 💡 Key takeaways include: • Strategies for securing funding at different stages of growth • The importance of innovation and partnerships in scaling • Lessons from Mercury’s work with biotech founders 🔗 Tune in to discover how Mercury is shaping the future of biotech financing. Link in comments! #BiotechFunding #StartupGrowth #BiotechInnovation #Mercury #Investors #TechTransfer #BiotechIndustry #HealthcareInnovation

🌱 Shaping the future of biotech: Creating a 'seedable' company At #BioFIT2024, the session "Gear up for years to come: How to get a ‘seedable’ company?" brought invaluable insights into the critical pre-seed funding stage for biotech ventures. 🎯 The panel explored the key ingredients needed to build a company that attracts investors and prepares for long-term success. From understanding investor expectations to the role of TTOs and incubators and building a governance-ready dream team, this session delivered actionable strategies for early-stage biotech companies. 🚀 A huge thank you to our incredible speakers: Shobhit D., Fund Manager, Oncode Bridge Fund  Ulrich Mahr, Member General Manager, Max-Planck-Innovation GmbH Jeroen Blokhuis, Head of Academic Innovation Sourcing and VC Partnership Europe, General Inception Marie Duranteau, Associate, Program Manager, Sofinnova Partners Your expertise and advice are sure to inspire the next wave of biotech innovators! 💡 Eline Delcroix Mathilde Wozniak 

With less than a week until our third annual Cavenagh Health Investor Breakfast, meet some of our distinguished panellists! As we aim to explore answers to the critical question: “From Defense to Offence: Is Now the Time to Shift Investment Strategies?” our panel of industry leaders will discuss strategies to navigate uncertainty in our current high-stakes investment landscape, Our first panellist is Debora Dumont, co-founder and Managing Partner of Bioqube Ventures. With a wealth of experience as a board member across biotech companies and her involvement in numerous international venture capital transactions, Debora brings invaluable insights and expertise across the industry to the panel. Our second panellist is the Managing Partner at Wellington Partners, Regina Hodits. Since joining the industry in 2000, she has become an influential investor in the European VC sector, specialising in early-stage and growth deals within Life Sciences. On the panel, we'll also welcome Ingrid Teigland Akay, MD MBA, Managing Partner at Hadean Ventures, who is also a medical doctor and experienced investment professional with a background in healthcare, consumer goods, and technology. This is set to be a morning packed with insightful discussions on navigating the complexities of today's market. If you’re an investor interested in attending, please contact Stephanie Murtagh for details. #HealthcareInvestment #LifeSciences #InvestmentStrategies #CavenaghHealth #JefferiesHealthcareBreakfast #ImpactInvesting #Biotech

💼🚀 Explore the Dynamics of Biotech Financing! Join us for the 'Venture & Private Equity Roundtable' at the #Sachs_BEF on September 25th, 2024, at the Mövenpick Hotel Basel. Dive into the world of venture capital and private equity that fuels the biotech industry’s growth and innovation. Co-Chaired by: Marianne Uteng, Managing Director, Novartis Venture Fund Steven Dickman, CEO, CBT Advisors Panellists: Cindy Daniel, Head of Unit - Life Sciences & Healthcare - Equity Investments, European Investment Fund (EIF) Hubert Birner, Managing Partner, TVM Capital Life Science Magne Stoknes, Principal, Novo Holdings A/S Matthieu Coutet, Partner, Sofinnova Partners Nigel Sheail, Venture Partner, Versant Ventures This roundtable will feature an in-depth discussion with leading venture capitalists and private equity investors who are shaping the future of biotech. Gain insights into investment trends, strategies for navigating the funding landscape, and perspectives on upcoming market opportunities in the biotech sector. Don't miss this chance to connect with industry leaders and financial experts. Secure your spot today at www.sachsforum.com/24bef and be part of this enlightening discussion, both #InPerson & #Online, during the Sachs Autumn Life Sciences Week. #BiotechVC #PrivateEquity #BiotechFunding #InvestmentTrends #LifeSciences #VentureCapital #Biotech #SALSW

💼 EIS Investor Panel: Tips for Attracting Venture Capital in Retinal Innovation During the EURETINA Innovation Spotlight (EIS), venture capital experts shared valuable insights for retina specialists and researchers seeking funding for their innovative ideas. Representatives from SOFINNOVA PARTNERS, BIOGENERATION VENTURES, and MONOGRAPH BIO discussed the evolution of investment in retinal treatments over the past decade and what investors are looking for today. Here are some key takeaways: 💡 Lower-risk innovations are increasingly attractive, such as improving drug delivery and duration. 📈 Excite investors with science—investors are drawn to the full picture, from development potential to market size. 💪 Demonstrate clear advantages—ensure your innovation has an easy-to-prove, significant benefit. 🤝 Choose your partners wisely—investor relationships are partnerships, so align your goals. 🔗 Read the full article on the Euretina Congress Daily website: https://ow.ly/I5Xq50TKsVh #EURETINA24 #RetinaCare #VentureCapital #InvestmentTips #InnovationInOphthalmology #EIS2024

🧬 Biotech Founders & Investors: Don't Miss This Panel! Unlocking Value in Early-Stage Biotech: Navigating the Pre-Clinical Valuation Puzzle Are you grappling with the challenges of valuing pre-clinical assets? Join us for an insightful discussion that could revolutionize your approach to biotech valuation and investment! 🔍 Key Focus Areas: • Scientific risk assessment and its impact on valuation • Building value through strategic partnerships and milestones • Market potential and competitive landscape analysis 🎙️ Expert Panelists: • Emily P., Principal, DCVC Bio • Reetika B., Senior Associate, ARCH Venture Partners • Fabio Pucci, Senior Director, Venture Investments, Leaps by Bayer These seasoned investors will share their invaluable insights on: ✅ How investors assess the potential of early-stage biotech assets ✅ Key drivers of valuation in the pre-clinical stage ✅ Strategies for attracting investment despite high scientific uncertainty 🗓️ March 10-11, 2025 📍 Miami - Sun, Sand, and Startups Ready to unlock the secrets of early-stage biotech valuation? Register now! 🔗 https://lnkd.in/eUnJhpfJ #InvestivalUSA #Biotechnology #biotech #biopharma #biotechleaders #BiotechInvestment #PreclinicalValuation #VentureCapital #BiopharmaInnovation Who's joining us in Miami? Tag a biotech founder or investor who needs to be there! 👇

🚀 Dear Life Sciences Investors, The MedCity summer pitch event is only a week away on the 2nd of July! We have received applications from 38 life sciences companies spanning all sub-sectors, including digital health, advanced therapies, SAAS, MedTech, diagnostics, sustainability, and more. These companies showcase innovative technology and exceptional talent. 👉 Sign up for the event here and join us to meet these cutting-edge SMEs. Your support is crucial for the life sciences pipeline. https://lnkd.in/eqwFXBzt Although we would have loved to have all applicants present, we've chosen the top 10 after a thorough due diligence process. If you're interested in specific life sciences sub-sectors, feel free to request pitch decks. I will gladly connect you with the founders and share their decks. Looking forward to seeing you there and fostering innovation in life sciences together! 🌟 #LifeSciences #MedCity #Innovation #Investors #PitchEvent #DigitalHealth #MedTech #AdvancedTherapies #Diagnostics #Sustainability

🙌🏽 Excited about Ontario’s new Life Sciences Scale-Up Fund (LSSUF) which will provide financial support to small- to medium-sized life sciences enterprises to scale up, innovate, and increase competitiveness.  ONeconomy | ÉconomieON    📅 Applications opening next week, on January 20!     Learn more:  ➡️ https://lnkd.in/gjmxj5Up     #lifesciences #healthtech #innovations #Innovators #LSSUF 

The Life Sciences Scale-up Fund (LSSUF) provides financial support to help small-to-medium sized enterprises (SMEs) scale up in the life sciences sector. LSSUF aims to help build a pipeline of strong innovative SMEs based in Ontario (or intending to relocate to Ontario) that are ready to respond to procurement opportunities. Another way the Ontario Government’s Life Sciences Strategy is supporting the sector. To learn more click on the link here. Life Sciences Ontario